Rapid steroid withdrawal in hepatitis C virus-positive kidney transplant recipients

Enver Akalin, Barbara Murphy, Vinita Sehgal, Scott Ames, Lisa Daly, Jonathan S. Bromberg

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The effects of rapid steroid withdrawal (SW) on kidney transplantation (KT) outcome were investigated in 12 HCV+ patients in a prospective cohort study. These results were compared with 17 HCV+ patients who received KT in the prior 2 yr and treated with a standard prednisone taper protocol. SW patients received only 6 d of steroid treatment after transplantation. Eleven received Thymoglobulin and one Basiliximab induction treatment along with a calcineurin inhibitor and mycophenolate mofetil. Patient and graft survival was 92% in SW group (median follow-up 12 months, range 6-17), and 92 and 82% in the historic control group respectively (median follow-up 21 months, range 11-27). In the SW and control-group, acute rejection rates were 9 and 18%, and mean creatinine levels at last follow-up 1.30 ± 0.36 and 1.68 ± 0.58 mg/dL respectively. Only two SW patients had an increase in liver function tests during follow-up (18%), compared with six patients in the control group (43%). This study demonstrates that rapid SW is safe for HCV+ KT recipients, without an increase in acute rejection episodes or liver function abnormalities in the short term.

Original languageEnglish (US)
Pages (from-to)384-389
Number of pages6
JournalClinical Transplantation
Volume18
Issue number4
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Hepacivirus
Steroids
Kidney
Kidney Transplantation
Control Groups
Mycophenolic Acid
Liver Function Tests
Graft Survival
Prednisone
Transplant Recipients
Creatinine
Cohort Studies
Transplantation
Prospective Studies
Liver
Therapeutics

Keywords

  • Hepatitis C virus
  • Kidney transplantation
  • Steroid withdrawal
  • Thymoglobulin

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Rapid steroid withdrawal in hepatitis C virus-positive kidney transplant recipients. / Akalin, Enver; Murphy, Barbara; Sehgal, Vinita; Ames, Scott; Daly, Lisa; Bromberg, Jonathan S.

In: Clinical Transplantation, Vol. 18, No. 4, 08.2004, p. 384-389.

Research output: Contribution to journalArticle

Akalin, Enver ; Murphy, Barbara ; Sehgal, Vinita ; Ames, Scott ; Daly, Lisa ; Bromberg, Jonathan S. / Rapid steroid withdrawal in hepatitis C virus-positive kidney transplant recipients. In: Clinical Transplantation. 2004 ; Vol. 18, No. 4. pp. 384-389.
@article{fb507b8d13fb4f049d4caceeb1600348,
title = "Rapid steroid withdrawal in hepatitis C virus-positive kidney transplant recipients",
abstract = "The effects of rapid steroid withdrawal (SW) on kidney transplantation (KT) outcome were investigated in 12 HCV+ patients in a prospective cohort study. These results were compared with 17 HCV+ patients who received KT in the prior 2 yr and treated with a standard prednisone taper protocol. SW patients received only 6 d of steroid treatment after transplantation. Eleven received Thymoglobulin and one Basiliximab induction treatment along with a calcineurin inhibitor and mycophenolate mofetil. Patient and graft survival was 92{\%} in SW group (median follow-up 12 months, range 6-17), and 92 and 82{\%} in the historic control group respectively (median follow-up 21 months, range 11-27). In the SW and control-group, acute rejection rates were 9 and 18{\%}, and mean creatinine levels at last follow-up 1.30 ± 0.36 and 1.68 ± 0.58 mg/dL respectively. Only two SW patients had an increase in liver function tests during follow-up (18{\%}), compared with six patients in the control group (43{\%}). This study demonstrates that rapid SW is safe for HCV+ KT recipients, without an increase in acute rejection episodes or liver function abnormalities in the short term.",
keywords = "Hepatitis C virus, Kidney transplantation, Steroid withdrawal, Thymoglobulin",
author = "Enver Akalin and Barbara Murphy and Vinita Sehgal and Scott Ames and Lisa Daly and Bromberg, {Jonathan S.}",
year = "2004",
month = "8",
doi = "10.1111/j.1399-0012.2004.00177.x",
language = "English (US)",
volume = "18",
pages = "384--389",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Rapid steroid withdrawal in hepatitis C virus-positive kidney transplant recipients

AU - Akalin, Enver

AU - Murphy, Barbara

AU - Sehgal, Vinita

AU - Ames, Scott

AU - Daly, Lisa

AU - Bromberg, Jonathan S.

PY - 2004/8

Y1 - 2004/8

N2 - The effects of rapid steroid withdrawal (SW) on kidney transplantation (KT) outcome were investigated in 12 HCV+ patients in a prospective cohort study. These results were compared with 17 HCV+ patients who received KT in the prior 2 yr and treated with a standard prednisone taper protocol. SW patients received only 6 d of steroid treatment after transplantation. Eleven received Thymoglobulin and one Basiliximab induction treatment along with a calcineurin inhibitor and mycophenolate mofetil. Patient and graft survival was 92% in SW group (median follow-up 12 months, range 6-17), and 92 and 82% in the historic control group respectively (median follow-up 21 months, range 11-27). In the SW and control-group, acute rejection rates were 9 and 18%, and mean creatinine levels at last follow-up 1.30 ± 0.36 and 1.68 ± 0.58 mg/dL respectively. Only two SW patients had an increase in liver function tests during follow-up (18%), compared with six patients in the control group (43%). This study demonstrates that rapid SW is safe for HCV+ KT recipients, without an increase in acute rejection episodes or liver function abnormalities in the short term.

AB - The effects of rapid steroid withdrawal (SW) on kidney transplantation (KT) outcome were investigated in 12 HCV+ patients in a prospective cohort study. These results were compared with 17 HCV+ patients who received KT in the prior 2 yr and treated with a standard prednisone taper protocol. SW patients received only 6 d of steroid treatment after transplantation. Eleven received Thymoglobulin and one Basiliximab induction treatment along with a calcineurin inhibitor and mycophenolate mofetil. Patient and graft survival was 92% in SW group (median follow-up 12 months, range 6-17), and 92 and 82% in the historic control group respectively (median follow-up 21 months, range 11-27). In the SW and control-group, acute rejection rates were 9 and 18%, and mean creatinine levels at last follow-up 1.30 ± 0.36 and 1.68 ± 0.58 mg/dL respectively. Only two SW patients had an increase in liver function tests during follow-up (18%), compared with six patients in the control group (43%). This study demonstrates that rapid SW is safe for HCV+ KT recipients, without an increase in acute rejection episodes or liver function abnormalities in the short term.

KW - Hepatitis C virus

KW - Kidney transplantation

KW - Steroid withdrawal

KW - Thymoglobulin

UR - http://www.scopus.com/inward/record.url?scp=4043090635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4043090635&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2004.00177.x

DO - 10.1111/j.1399-0012.2004.00177.x

M3 - Article

C2 - 15233814

AN - SCOPUS:4043090635

VL - 18

SP - 384

EP - 389

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 4

ER -